Clinical trial / 1982
Amygdalin and metabolic therapy showed no cancer benefits and presented cyanide toxicity risks
One hundred seventy-eight cancer patients received amygdalin alongside a metabolic regimen of diet, enzymes, and vitamins. The treatment produced no measurable cure, tumor stabilization, symptom relief, or prolonged survival. Several participants experienced manifestations of cyanide toxicity, with blood cyanide concentrations nearing fatal thresholds.
- Study type
- Uncontrolled clinical trial
- Who was studied
- 178 patients with cancer
- What was measured
- Cancer progression, symptom relief, survival, and cyanide toxicity
THE PAPER
A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.
Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP. N Engl J Med, 1982.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.